Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Relypsa Inc.

Division of Vifor Pharma Group

Latest From Relypsa Inc.

Pipeline Watch: Phase III Starts With DCC-2618, Tislelizumab And Tabelecleucel

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

The 'New' Vifor Pharma: Focused On Specialty Pharma

With a new hyperkalemia therapy nearing EU markets and its injectable iron product showing strong sales growth, Switzerland’s global specialty pharma company Vifor Pharma has been able to upgrade its financial guidance for 2017.

Business Strategies Commercial

Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda

First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.

Financing StartUps and SMEs

Vifor Becomes A 'Pure Play' Pharma

A Swiss IPO for retail pharmacy and distributor spin-off Galenica Santé has allowed the remaining specialty firm Vifor Pharma to become a pure play pharma with a potential blockbuster potassium binder Veltassa and interests in renal disease, iron replacement and cardio-renal disorders.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vifor Pharma Group
  • Senior Management
  • John A Orwin, CEO
    Stephen D Harrison, PhD, SVP, CSO
    Lance Berman, MD, SVP, CMO
    Scott Garland, SVP, Chief Commercial Officer
    Camille Landis, VP, Bus. Dev.
  • Contact Info
  • Relypsa Inc.
    Phone: (650) 421-9500
    100 Cardinal Way
    Redwood City, CA 94063